We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$2.19B
Turnover
34.18%
1-Year Est. Return
374.99%
This Fund
S&P 500
This Quarter
Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
(+29%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
7.61%
Top 10 Holdings %
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
1.1
years
Top 20 Avg Time Held Equity + Options
0.9
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
1.3
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$46.5M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$38.5M |
| 3 |
Zai Lab
ZLAB
|
+$38.4M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$34.8M |
| 5 |
Editas Medicine
EDIT
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$48.2M |
| 2 |
Beam Therapeutics
BEAM
|
+$34.5M |
| 3 |
Scholar Rock
SRRK
|
+$20M |
| 4 |
Denali Therapeutics
DNLI
|
+$17.3M |
| 5 |
Cytokinetics
CYTK
|
+$12.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.67% |
| 2 | Miscellaneous | 11.02% |
| 3 | Financials | 2.15% |
| 4 | Real Estate | 0.05% |
| 5 | Communication Services | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
226
CNS Pharmaceuticals
CNSP
$7.82M
| $335K | 0.02% |
+70,000
| New | +$294K |
2026 Q2
0 quarters
|
|
227
Crescent Biopharma
CBIO
$467M
| $329K | 0.02% |
18,275
-31,998
| -64% | -$625K |
2025 Q4
2 quarters
|
|
228
Boston Scientific
BSX
$62.3B
| $320K | 0.01% |
7,500
-2,500
| -25% | -$136K |
2025 Q4
2 quarters
|
|
229
Altimmune
ALT
$449M
| $313K | 0.01% |
+102,823
| New | +$307K |
2026 Q2
0 quarters
|
|
230
Verastem
VSTM
$698M
| $290K | 0.01% |
75,800
+4,700
| +7% | +$22.7K |
2026 Q1
1 quarter
|
|
231
AN2 Therapeutics
ANTX
$134M
| $285K | 0.01% |
58,808
+44,947
| +324% | +$193K |
2026 Q1
1 quarter
|
|
232
Journey Medical
DERM
$149M
| $280K | 0.01% |
+39,517
| New | +$226K |
2026 Q2
0 quarters
|
|
233
ProCap Acquisition Corp Unit
PCAPU
| $279K | 0.01% |
26,940
| – | – |
2025 Q2
4 quarters
|
|
234
PMV Pharmaceuticals
PMVP
$66.3M
| $269K | 0.01% |
201,008
-30,000
| -13% | -$38.5K |
2024 Q1
9 quarters
|
|
235
Compass Therapeutics
CMPX
$158M
| $267K | 0.01% |
122,132
-16,868
| -12% | -$49.8K |
2025 Q2
4 quarters
|
|
236
JD.com
JD
$36B
| $255K | 0.01% |
10,000
| – | – |
2025 Q3
3 quarters
|
|
237
Rezolute
RZLT
$409M
| $253K | 0.01% |
48,679
-10,000
| -17% | -$37.1K |
2024 Q2
8 quarters
|
|
238
AnaptysBio
ANAB
$1.4B
| $250K | 0.01% |
3,698
| – | – |
2026 Q1
1 quarter
|
|
239
Neurogene
NGNE
$444M
| $245K | 0.01% |
+7,800
| New | +$215K |
2026 Q2
0 quarters
|
|
240
iShares US Medical Devices ETF
IHI
$3.66B
| $242K | 0.01% |
+4,900
| New | +$249K |
2026 Q2
0 quarters
|
|
241
RxSight
RXST
$188M
| $241K | 0.01% |
50,000
+6,750
| +16% | +$40.7K |
2025 Q4
2 quarters
|
|
242
Coya Therapeutics
COYA
$98.1M
| $239K | 0.01% |
40,900
| – | – |
2026 Q1
1 quarter
|
|
243
Bicycle Therapeutics
BCYC
$246M
| $215K | 0.01% |
50,638
-20,660
| -29% | -$94.7K |
2026 Q1
1 quarter
|
|
244
Cantor Equity Partners VI
CEPS
$150M
| $207K | 0.01% |
20,000
| – | – |
2026 Q1
1 quarter
|
|
245
SCYNEXIS
SCYX
$39.4M
| $201K | 0.01% |
+49,387
| New | +$307K |
2026 Q2
0 quarters
|
|
246
Personalis
PSNL
$1.7B
| $201K | 0.01% |
15,000
-10,000
| -40% | -$81.4K |
2026 Q1
1 quarter
|
|
247
Q/C Technologies Inc
QCLS
$4.42M
| $195K | 0.01% |
50,000
| – | – |
2026 Q1
1 quarter
|
|
248
Cabaletta Bio
CABA
$275M
| $156K | 0.01% |
+50,000
| New | +$164K |
2026 Q2
0 quarters
|
|
249
Recursion Pharmaceuticals
RXRX
$2.01B
| $150K | 0.01% |
41,000
+6,000
| +17% | +$20K |
2024 Q3
7 quarters
|
|
250
Organon & Co
OGN
$3.61B
| $135K | 0.01% |
10,000
| – | – |
2024 Q1
9 quarters
|
|
Similar funds
GAMH
RCAG
AF
AWM
TCM
WRBC
IAN
BOI
ADAR1 Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.
- ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
- ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
- ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
- ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
- ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
- ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
- ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.
Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.